白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2014年
8期
503-506
,共4页
淋巴瘤%利妥昔单抗%造血干细胞移植%移植物抗宿主病
淋巴瘤%利妥昔單抗%造血榦細胞移植%移植物抗宿主病
림파류%리타석단항%조혈간세포이식%이식물항숙주병
Lymphoma%Rituximab%Hematopoietic stem cell transplantation%Graft-versus-host disease
由于毒性较低且具有抗淋巴瘤活性,利妥昔单抗被纳入淋巴瘤的移植治疗中.其不仅可提高疗效,减少移植后疾病复发,还可发挥免疫调节作用,有利于移植物抗宿主病的防治.文章对利妥昔单抗在自体和异基因造血干细胞移植治疗淋巴瘤中的应用作一综述.
由于毒性較低且具有抗淋巴瘤活性,利妥昔單抗被納入淋巴瘤的移植治療中.其不僅可提高療效,減少移植後疾病複髮,還可髮揮免疫調節作用,有利于移植物抗宿主病的防治.文章對利妥昔單抗在自體和異基因造血榦細胞移植治療淋巴瘤中的應用作一綜述.
유우독성교저차구유항림파류활성,리타석단항피납입림파류적이식치료중.기불부가제고료효,감소이식후질병복발,환가발휘면역조절작용,유리우이식물항숙주병적방치.문장대리타석단항재자체화이기인조혈간세포이식치료림파류중적응용작일종술.
Owing to its low toxicity and high anti-lymphoma activity,rituximab has been applied in the transplantation for lymphoma.It can not only improve the therapeutic effecr and reduce the recurrence of the disease,but also play a role in immunoregulation,which favors the prevention and treatment of graftversus-host disease.In this paper,the application of rituximab in hematopoietic stem cell transplantation for lymphoma was reviewed.
